Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study
- 681 Downloads
Rituximab is considered as a potential therapeutic option in relapsing-remitting (RRMS) and progressive forms (PMS) of multiple sclerosis (MS).
To investigate the effectiveness and safety of rituximab in MS.
Patients and methods
Observational study of effectiveness (clinical and radiological) and safety of rituximab in RRMS and PMS.
A total of 90 rituximab-treated patients were collected: 31 RRMS and 59 PMS All patients had an active disease despite standard treatment. The annualized relapse rate (ARR) the year before rituximab was 0.86, 53.3% of patients had gadolinium enhanced lesion, and mean Expanded Disability Status Scale (EDSS) had increased from 4.2 to 4.9. During treatment, the ARR was reduced an 88.4% (p < 0.001). A significant decrease of EDSS to 4.6 was observed (p = 0.01) after 1 year of treatment, which remained stable during the second year in both groups. There was no evidence of disease activity in 70% of total sample, 74.2% of RRMS, and 67% of the PMS patients. Infusion-related symptoms were the most prevalent side effect (18.8%) and most were mild. Three thrombotic events were detected.
Rituximab could be an effective and safe treatment in aggressive RRMS. Some selected PMS patients could also benefit from this treatment.
KeywordsMultiple sclerosis Relapsing-remitting multiple sclerosis Progressive multiple sclerosis Treatment Rituximab Anti-CD20 monoclonal antibody
Compliance with ethical standards
Conflicts of interest
The authors declare that they have no conflict of interest.
All patients included in the study acceded to donate and signed a specific informed consent and all research was conducted following legal and ethical requirements at the Research Institute of the Hospital La Fe and was approved by its Institutional Review Board.
- 16.Ferraro D, Simone AM, Bedin R et al (2013) Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with Clinically Isolated Syndrome. J Neuroimmunol 257:76–81. https://doi.org/10.1016/j.jneuroim.2013.01.011 CrossRefPubMedGoogle Scholar
- 19.Bosca I, Pascual AM, Casanova B et al (2008) Four new cases of therapy-related acute promyelocytic leukemia after mitoxantrone. Neurology 71:457–458. https://doi.org/10.1212/01.wnl.0000324422.69067.e7 CrossRefPubMedGoogle Scholar
- 23.Dada R, Zekri J, Ramal B, Ahmad K Acute jugular vein thrombosis during rituximab administration: review of the literature. J Oncol Pharm Pract 22:165–169. https://doi.org/10.1177/1078155214543278